bioAffinity Technologies, Inc. - 8-K Filing
CyPath® Lung sales for Q2 2026 grew more than 200% year-over-year and increased by over 30% compared to the prior quarter. The growth was driven by higher utilization among existing clients and a 155% increase in physician offices ordering CyPath® Lung as of July 7, 2026. (Items: 8.01 Other Events, 9.01 Financial Statements and Exhibits)
Tickers: $BIAF